RxDoctor Payments Data

Callum McCormick

Internal Medicine · Irving, TXNPI 1831551589

Payments from drug & device makers

$400in general payments, 2019–2025

Across 24 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$53
  • Novo Nordisk$53
  • AbbVie$51
  • Sanofi-aventis U.S. LLC$35
  • Amgen$32
  • Lilly USA, LLC$30
  • plus $146 from 7 others

What the payments were for

  • Food & beverage$400100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$400 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$41,232
Medicare patients
133
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide56$68,546
OzempicSemaglutide59$67,010
EliquisApixaban57$49,894
JardianceEmpagliflozin36$42,526
JanuviaSitagliptin Phosphate23$25,714
TrulicityDulaglutide11$17,359
XareltoRivaroxaban14$15,029
FarxigaDapagliflozin Propanediol15$14,128
SymbicortBudesonide/Formoterol Fumarate18$7,609
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,027
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$6,131
Tresiba Flextouch U-100Insulin Degludec11$4,152
Incruse ElliptaUmeclidinium Bromide11$3,950
Fluticasone Propionate232$3,117
Atorvastatin Calcium278$1,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$30$85,90567 claims
Novo NordiskOzempic$53$67,01059 claims
PfizerEliquis$29$49,89457 claims
Boehringer IngelheimJardiance$53$42,52636 claims
AstraZenecaFarxiga, Symbicort$18$21,73733 claims
GSKTrelegy Ellipta, Incruse Ellipta$18$10,97722 claims
AbbVieSynthroid$51$98014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Irving

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →